SIGLEC1 (Sialic Acid-Binding Ig-Like Lectin 1), also known as CD169, Sialoadhesin, or Siglec-1, encodes a cell surface receptor belonging to the siglec family of sialic acid-binding lectins. Originally identified as a marker for activated macrophages, SIGLEC1 plays critical roles in immune recognition, cell-cell interactions, and the clearance of pathogens. More recently, SIGLEC1 has emerged as a significant factor in neurodegenerative disease pathogenesis through its involvement in neuroinflammation, amyloid-beta clearance, and immune modulation in the brain.
SIGLEC1 is expressed primarily on monocytes and macrophages throughout the body, including in the brain where it marks a specific subset of macrophages with distinct functional properties. Its ability to recognize sialylated glycans on host cells and pathogens makes it a unique interface between innate immunity and tissue homeostasis. In neurodegenerative diseases like Alzheimer's and Parkinson's, SIGLEC1-expressing macrophages may influence disease progression through their roles in clearing or potentially propagating pathological proteins.
| SIGLEC1 Gene |
|---|
| Gene Symbol | SIGLEC1 |
| Full Name | Sialic Acid-Binding Ig-Like Lectin 1 |
| Chromosomal Location | 20p13 |
| NCBI Gene ID | [6614](https://www.ncbi.nlm.nih.gov/gene/6614) |
| OMIM ID | 600738 |
| Ensembl ID | [ENSG00000105550](https://www.ensembl.org/Homo_sapiens/ENSG00000105550) |
| UniProt ID | [Q9PMN3](https://www.uniprot.org/uniprot/Q9PMN3) |
| Protein Length | 1644 amino acids |
| Protein Class | Siglec Family (I-type lectin) |
| Aliases | CD169, Sialoadhesin, SN |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimer-disease), [Parkinson's Disease](/diseases/parkinson-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), HIV-associated neurocognitive disorder |
¶ Domain Architecture
SIGLEC1 possesses a characteristic siglec structure:
-
Extracellular Domain:
- N-terminal V-type Ig domain: Contains the sialic acid-binding site
- C2-type Ig domains (16 repeats): Form the stalk region
- Mucin-like region: Provides extended structure
-
Transmembrane Domain:
- Single transmembrane helix: Anchors the protein in the plasma membrane
- Basic residue motif: Important for membrane association
-
Cytoplasmic Domain:
- Immunoreceptor Tyrosine-based Inhibition Motifs (ITIMs): Two ITIM sequences
- Signaling capacity: Recruits phosphatases for signal modulation
- Sialic acid binding: The N-terminal domain specifically recognizes α2,3-linked and α2,6-linked sialic acids
- Extended structure: The mucin-like region extends the ligand-binding domain away from the cell surface
- ITIM signaling: Provides inhibitory signaling capacity
SIGLEC1 serves multiple immune functions:
- Sialic Acid Recognition: Binds to sialylated glycans on host cells and pathogens
- Phagocyte Receptor: Mediates binding to sialylated ligands on target cells
- Immune Regulation: Modulates inflammatory responses in macrophages and microglia
- Cell Adhesion: Facilitates cell-cell interactions in immune tissues
- Pathogen Clearance: Recognizes sialylated patterns on microbes
SIGLEC1 transduces signals through its cytoplasmic tail:
- ITIM Motifs: Contain immunoreceptor tyrosine-based inhibition sequences
- Phosphatase Recruitment: ITIMs recruit SHP-1 and SHP-2 phosphatases
- Modulation of Activation: Lowers immune cell activation thresholds
- Anti-inflammatory Effects: Can suppress excessive immune responses
SIGLEC1 shows specific expression patterns:
- Spleen: Highest expression in marginal zone macrophages
- Lymph Nodes: Expressed on subcapsular sinus macrophages
- Bone Marrow: Present on specific macrophage subsets
- Brain: Expressed on activated microglia in disease states
SIGLEC1 has significant implications for AD pathogenesis:
- Microglial Activation: SIGLEC1 marks a specific activated microglial population in AD brain. These CD169+ microglia cluster around amyloid plaques and represent a disease-associated state.
- Amyloid-beta Binding: SIGLEC1 can bind to amyloid-beta peptides, potentially facilitating their clearance by macrophages. The sialic acid-binding property may be involved in Aβ recognition.
- Neuroinflammation: SIGLEC1+ macrophages produce pro-inflammatory cytokines that contribute to chronic neuroinflammation. The balance between protective clearance and harmful inflammation remains under investigation.
- Expression Correlation: SIGLEC1 expression correlates with disease severity and plaque burden. Higher levels are seen in more advanced disease stages.
- Therapeutic Target: Targeting SIGLEC1 represents a potential approach to modulate microglial function in AD.
SIGLEC1 connections to PD include:
- Neuroinflammation: SIGLEC1+ macrophages are present in PD brain and contribute to dopaminergic neuron loss. These cells are found in the substantia nigra and other affected regions.
- Alpha-synuclein Clearance: Evidence suggests SIGLEC1 may be involved in α-synuclein clearance mechanisms. Macrophages can take up α-synuclein, and SIGLEC1 may participate in this process.
- Peripheral Inflammation: SIGLEC1 expression on peripheral monocytes is altered in PD. This may reflect systemic inflammatory changes in the disease.
- Disease Progression: SIGLEC1 expression levels may correlate with disease progression and severity.
SIGLEC1 plays multiple roles in MS:
- Demyelination: SIGLEC1+ macrophages are involved in myelin clearance in active lesions. They phagocytose myelin debris in evolving demyelinating lesions.
- Inflammatory Lesions: High SIGLEC1 expression in MS lesions correlates with active inflammation. The CD169+ macrophage population is prominent in acute and chronic active lesions.
- Biomarker Potential: Cerebrospinal fluid SIGLEC1 levels may serve as a disease activity marker. Elevated levels correlate with clinical exacerbations.
- Therapeutic Target: Modulating SIGLEC1+ macrophage function may reduce demyelination and promote repair.
¶ HIV-Associated Neurocognitive Disorder (HAND)
SIGLEC1 is implicated in HIV neuropathogenesis:
- Viral Entry: SIGLEC1 can mediate HIV binding to macrophages, facilitating viral entry into these cells. This represents a mechanism for viral reservoirs in the brain.
- Neuroinflammation: SIGLEC1+ macrophages contribute to chronic neuroinflammation in HIV. These cells produce inflammatory mediators that affect neuronal function.
- Cognitive Decline: SIGLEC1 expression correlates with cognitive impairment in HIV patients. Higher levels are associated with more severe neurocognitive deficits.
SIGLEC1 binding involves:
- Sialylated Ligands: Recognizes specific sialylated glycoconjugates
- Glycan Specificity: Prefers certain sialyl linkages (α2,3 and α2,6)
- Pattern Recognition: Can distinguish between self and non-self sialylation
ITIM-mediated signaling includes:
- Tyrosine Phosphorylation: ITIM tyrosines become phosphorylated upon ligand binding
- Phosphatase Recruitment: SHP-1 and SHP-2 are recruited to phosphorylated ITIMs
- Signaling Inhibition: Phosphatase activity dampens activating signals
- Immunomodulation: Overall effect is to modulate immune cell activation
SIGLEC1 interacts with:
- Sialylated proteins: Various sialylated targets
- SHP-1/SHP-2: Phosphatases for signal transduction
- Amyloid-beta: Direct binding in AD
- Alpha-synuclein: Potential interaction in PD
- Viral proteins: HIV gp120 binding
¶ Expression and Localization
SIGLEC1 shows disease-specific brain expression:
- Healthy Brain: Very low or undetectable expression
- Alzheimer's Disease: High expression in plaque-associated microglia
- Parkinson's Disease: Present in substantia nigra and other regions
- Multiple Sclerosis: High expression in active demyelinating lesions
- HIV Brain: Elevated expression in infected individuals
- Microglia: Activated microglia upregulate SIGLEC1
- Macrophages: Primary expressors in peripheral tissues
- Monocytes: Express SIGLEC1 upon activation
- Dendritic Cells: Some subsets express SIGLEC1
SIGLEC1-based therapies may address:
- Modulate Neuroinflammation: Reduce harmful inflammation while preserving beneficial functions
- Enhance Clearance: Promote clearance of pathological proteins
- Block Viral Entry: Prevent HIV infection of macrophages in CNS
- Monoclonal Antibodies: Anti-SIGLEC1 antibodies for immunomodulation
- Small Molecule Inhibitors: Sialic acid analogs as competitive inhibitors
- CAR-T Cells: SIGLEC1 as target for cell-based therapy
- Gene Therapy: Modulating SIGLEC1 expression
- CSF SIGLEC1: Cerebrospinal fluid levels as disease activity marker
- Peripheral Expression: Blood monocyte SIGLEC1 as biomarker
- Imaging: PET ligands for SIGLEC1 expression (in development)
- SIGLEC1 Transgenic Mice: For studying macrophage function
- Humanized Models: For HIV-related studies
- Flow Cytometry: Identify SIGLEC1+ cell populations
- Immunohistochemistry: Localize SIGLEC1 in tissues
- Functional Assays: Study phagocytosis and signaling
Understanding SIGLEC1 will help:
- Elucidate Neuroinflammation: Mechanisms of macrophage-mediated neuroinflammation
- Develop Therapeutics: Target SIGLEC1 for neurodegenerative disease treatment
- Identify Biomarkers: Develop diagnostic and prognostic markers
- Understand Immune Regulation: Basic mechanisms of siglec-mediated immunity